BackSprint Bioscience AB Overview

Sprint Bioscience AB Total Liabilities

Latest total liabilities for SPRINT.ST: $13M.

Get informed when a big investor buys or sells

+ Follow
Total Liabilities
$13.15M
↓ 14.47% YoYΔ $-2.22M vs prior year quarter

Peer trimmed avg / median

Loading

Sprint Bioscience AB Total Liabilities History

Loading

Sprint Bioscience AB vs. peers: Total Liabilities Comparison

Loading

Sprint Bioscience AB Total Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Sprint Bioscience AB (SPRINT.ST) FAQ

Sprint Bioscience AB posts a total liabilities of $13M as of September 2026. That compares with $15M in the prior-year period — down 14.5% year over year. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Sprint Bioscience AB's total liabilities was $15M. The latest reading is $13M — a 14.5% year-over-year decrease (period ending September 2026). Use the history and growth charts on this page for a longer lookback.

Total Liabilities is one piece of Sprint Bioscience AB's financial statement story. At $13M, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for SPRINT.ST's total liabilities usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Sprint Bioscience AB's other metric pages and overview cover the third.

Judging Sprint Bioscience AB against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in total liabilities easier to interpret. Start with $13M here, then scan peer and history charts to see if the gap is persistent.